Patent intelligence · US
US 12012384
Dextrorphan prodrugs and processes for making and using them
Dextrorphan prodrugs and processes for making and using them
Patent details — US 12012384
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 18, 2024
- Expiration
- Jun 13, 2044
- Applicant
- Zevra Therapeutics, Inc.
- Claims
- 4
- CPC classes
- A61K, A61K47/542, A61P, A61P11/14
Quick answer
US 12012384 (Dextrorphan prodrugs and processes for making and using them) is held by Zevra Therapeutics, Inc.. Status: granted. Granted Jun 18, 2024. Expires Jun 13, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Zevra Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K47/542, A61P, A61P11/14, A61P25/36
More from Zevra Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12251445
Gamma-hydroxybutyrate delivering compounds and processes for making and using them
granted -
US 12091386
D-amphetamine compounds, compositions, and processes for making and using the same
granted -
US 12076316
Levorphanol prodrugs and processes for making and using them
granted -
US 11938125
Use of Hsp70 as a regulator of enzymatic activity
granted
Frequently asked questions
What is US patent 12012384?
US 12012384 (Dextrorphan prodrugs and processes for making and using them) is held by Zevra Therapeutics, Inc.. Status: granted. Granted Jun 18, 2024. Expires Jun 13, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12012384?
Zevra Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 12012384 expire?
Our index shows an expiration date of Jun 13, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.